Study directory

Mental health studies with practical context.

Public study records, presented in a clearer and more patient-friendly format for mental health research discovery.

Back to overview
10592studies shown
Showing 7,909-7,920 of 10,592
Drug study icon
CompletedNCT05106309

Pharmacokinetics of CVL-231 Following Single Oral Administration of Modified- and Immediate-release Formulations in Fasted and Fed Healthy Participants

This study exists to explore whether the medication CVL-231 could improve care and understanding. Researchers are trying to understand what the medication CVL-231 could change in day-to-day care and decision-making.

In United States
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
Cerevel Therapeutics, LLC
Condition
Schizophrenia
Drug study icon
CompletedNCT01907360

Pharmacokinetics of HLD200 in Children and Adolescents With ADHD

This study exists to explore whether blood tests and biological markers could improve care and understanding. Researchers are trying to understand whether blood tests and biological markers can give earlier or clearer feedback during care.

In United States
ADHDDrugFrom 6 Years to 17 Years
Countries
United States
Sponsor
Ironshore Pharmaceuticals and Development, Inc
Condition
ADHD
Drug study icon
CompletedNCT02978534

Pharmacokinetics of Quetiapine Across Pregnancy and Postpartum

This study exists to explore whether smoking support or smoking-related treatment could improve care and understanding. Researchers are trying to understand whether smoking support or smoking-related treatment can work better when mental health difficulties overlap with substance use.

In United States
BipolarityDrugFrom 18 Years to 45 Years
Countries
United States
Sponsor
Northwestern University
Condition
Bipolarity
Drug study icon
CompletedNCT04709224

Pharmacokinetics, Safety, and Tolerability of Lumateperone Long-Acting Injectable in people with Schizophrenia

This study exists to learn from real-world information that can show how a medication treatment fits into care. Researchers are trying to understand how people respond to a medication treatment in practice and what may need to be adjusted.

In United States
SchizophreniaDrugFrom 18 Years to 50 Years
Countries
United States
Sponsor
Intra-Cellular Therapies, Inc.
Condition
Schizophrenia
Drug study icon
CompletedNCT04414930

Pharmacologic Augmentation of Targeted Cognitive Training in Schizophrenia

This study exists to see whether a therapy or guided support program is workable and worth testing more broadly. Researchers are trying to understand whether a therapy or guided support program can improve attention, thinking, or day-to-day functioning.

In United States
SchizophreniaDrugFrom 18 Years to 55 Years
Countries
United States
Sponsor
University of California, San Diego
Condition
Schizophrenia
Data coverage

Public registry coverage is progressing

HopeStage gathers information about mental health clinical trials from the public registries we currently index. We are progressively improving registry coverage, but this does not mean that every study in the world is already included.